SEC Form 4 · accession 0001213900-19-001279
Inspire Medical Systems, Inc. · INSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joyce Erony
Director
Period of report
Jan 23, 2019
Accepted (ET)
Jan 25, 2019 · 6:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609550
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F6 | Jan 23, 2019 | S | 12,773 | $52.401 | D | 894,161 | I | See Footnote |
| Common StockF3,F6 | Jan 24, 2019 | S | 27,118 | $52.3262 | D | 867,043 | I | See Footnote |
| Common StockF4,F6 | Jan 24, 2019 | S | 1,600 | $53.1261 | D | 865,443 | I | See Footnote |
| Common StockF5,F6 | Jan 25, 2019 | S | 21,379 | $53.0902 | D | 844,064 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.45 to $53.58. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.02 to $53.07. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.05 to $53.27. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.08 to $53.58. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. Ms. Erony disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.